{"transactions":[{"id":687797,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-08-13T20:10:23.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":47436,"price":4.4445,"value":210829.302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33  to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 193,254 shares represent restricted stock units."}],"balance_after":328651,"source":{"system":"sec-edgar","filing":"0001501697-26-000069","document":"wk-form4_1786651821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000150169726000069/wk-form4_1786651821.xml","form_type":"4"}},{"id":1010466,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-31T20:42:05.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":2329154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":2329154,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":2329154},"source":{"system":"sec-edgar","filing":"0001339498-25-000004","document":"wk-form4_1761943322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000133949825000004/wk-form4_1761943322.xml","form_type":"4"}},{"id":1013117,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-10-27T22:40:40.000Z","date":"2025-10-23","kind":"purchase","planned":false,"acquired":true,"shares":86206,"price":2.9,"value":249997.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of the Issuer's common stock purchased in connection with the Issuer's public offering."}],"balance_after":376087,"source":{"system":"sec-edgar","filing":"0001501697-25-000035","document":"wk-form4_1761604837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000150169725000035/wk-form4_1761604837.xml","form_type":"4"}},{"id":1066209,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":529201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":529201,"derivative":{"exercise_price":3.14,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":529201},"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1066208,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":1609873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":1609873,"derivative":{"exercise_price":1.42,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":1609873},"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1066207,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-08-15T00:31:21.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":289881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders."}],"balance_after":289881,"source":{"system":"sec-edgar","filing":"0001628280-25-040441","document":"wk-form4_1755217877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339498/000162828025040441/wk-form4_1755217877.xml","form_type":"4"}},{"id":1844622,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.55,"underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844621,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1115000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.49,"underlying":"Common Stock","underlying_shares":1115000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844620,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.3,"underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844619,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2320000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":2320000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844618,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":470054,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":0.8411,"underlying":"Common Stock","underlying_shares":470054},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844617,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1.88,"underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844616,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":475000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.14,"underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844615,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.19,"underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844614,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.24,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1844613,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-06-26T16:05:16.000Z","date":"2023-06-26","kind":"other","planned":false,"acquired":false,"shares":31470,"price":9.1,"value":286377.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 2,030 shares of common stock of the Issuer (\"Company Common Stock\") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-016480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016480/doc4.xml","form_type":"4"}},{"id":1951020,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-16T17:52:51.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates."}],"balance_after":900000,"derivative":{"exercise_price":4.55,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0000899243-23-008753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323008753/doc4.xml","form_type":"4"}},{"id":2045585,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"exercise","acquired":false,"shares":2117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":470054,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":2117},"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2045584,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"exercise","acquired":false,"shares":83200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":472171,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":83200},"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2045583,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":2117,"price":6.01,"value":12723.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2045582,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"exercise","acquired":true,"shares":2117,"price":0.8411,"value":1780.6087,"ownership":{"direct":true},"balance_after":31557,"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2045581,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":83200,"price":6,"value":499200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2045580,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-26T17:17:19.000Z","date":"2023-01-24","kind":"exercise","acquired":true,"shares":83200,"price":0.8411,"value":69979.52,"ownership":{"direct":true},"balance_after":112640,"source":{"system":"sec-edgar","filing":"0000891293-23-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000004/primary_doc.xml","form_type":"4"}},{"id":2073441,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T19:47:50.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":84683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":555371,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":84683},"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073440,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":640054,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073439,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":644454,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073438,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":645154,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073437,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-29","kind":"exercise","acquired":false,"shares":13800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":657154,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":13800},"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073436,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":84683,"price":6.0133,"value":509224.2839,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073435,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":84683,"price":0.8411,"value":71226.8713,"ownership":{"direct":true},"balance_after":114123,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073434,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":4400,"price":6.01,"value":26444.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073433,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":4400,"price":0.8411,"value":3700.84,"ownership":{"direct":true},"balance_after":33840,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073432,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":700,"price":6.005,"value":4203.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073431,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":700,"price":0.8411,"value":588.77,"ownership":{"direct":true},"balance_after":30140,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073430,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":12000,"price":6,"value":72000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073429,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":12000,"price":0.8411,"value":10093.2,"ownership":{"direct":true},"balance_after":41440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073428,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":1579,"price":5.1085,"value":8066.3215,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":29440,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073427,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-29","kind":"sale","acquired":false,"shares":13800,"price":6,"value":82800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":27861,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2073426,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2023-01-03T19:47:50.000Z","date":"2022-12-29","kind":"exercise","acquired":true,"shares":13800,"price":0.8411,"value":11607.18,"ownership":{"direct":true},"balance_after":41661,"source":{"system":"sec-edgar","filing":"0000891293-23-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129323000002/primary_doc.xml","form_type":"4"}},{"id":2118987,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"exercise","acquired":false,"shares":188304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":670954,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":188304},"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118986,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-09","kind":"exercise","acquired":false,"shares":53996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":859258,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":53996},"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118985,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":2700,"price":6.04,"value":16308.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":27861,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118984,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":5800,"price":6.03,"value":34974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":30561,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118983,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":16396,"price":6.02,"value":98703.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":36361,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118982,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":100,"price":6.015,"value":601.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":52757,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118981,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":26700,"price":6.01,"value":160467.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":52857,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118980,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":200,"price":6.005,"value":1201.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":79557,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118979,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":136408,"price":6,"value":818448.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":79757,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118978,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-10","kind":"exercise","acquired":true,"shares":188304,"price":0.8411,"value":158382.4944,"ownership":{"direct":true},"balance_after":216165,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118977,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":300,"price":6.015,"value":1804.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":27861,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118976,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":7596,"price":6.01,"value":45651.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":28161,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118975,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":46100,"price":6,"value":276600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person."}],"balance_after":35757,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2118974,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-11-14T16:42:55.000Z","date":"2022-11-09","kind":"exercise","acquired":true,"shares":53996,"price":0.8411,"value":45416.0356,"ownership":{"direct":true},"balance_after":81857,"source":{"system":"sec-edgar","filing":"0000891293-22-000056","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000056/primary_doc.xml","form_type":"4"}},{"id":2159664,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-09-14T16:35:33.000Z","date":"2022-09-12","kind":"exercise","acquired":false,"shares":242300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":913254,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":242300},"source":{"system":"sec-edgar","filing":"0000899243-22-031043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322031043/doc4.xml","form_type":"4"}},{"id":2159663,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-14T16:35:33.000Z","date":"2022-09-12","kind":"sale","acquired":false,"shares":242300,"price":6.43,"value":1557989.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 5,000 shares of common stock purchased by the reporting person on August 16, 2022. The reporting person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.27 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":27861,"source":{"system":"sec-edgar","filing":"0000899243-22-031043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322031043/doc4.xml","form_type":"4"}},{"id":2159662,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-14T16:35:33.000Z","date":"2022-09-12","kind":"exercise","acquired":true,"shares":242300,"price":0.8411,"value":203798.53,"ownership":{"direct":true},"balance_after":270161,"source":{"system":"sec-edgar","filing":"0000899243-22-031043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322031043/doc4.xml","form_type":"4"}},{"id":2184856,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-08-16T16:07:58.000Z","date":"2022-08-16","kind":"purchase","acquired":true,"shares":5000,"price":5.5,"value":27500.0,"ownership":{"direct":true},"balance_after":27861,"source":{"system":"sec-edgar","filing":"0000891293-22-000044","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000044/primary_doc.xml","form_type":"4"}},{"id":2213016,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-06","kind":"exercise","acquired":false,"shares":18223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1155554,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":18223},"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213015,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-05","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1173777,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213014,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-01","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1200777,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213013,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-06","kind":"sale","acquired":false,"shares":18223,"price":6.11,"value":111342.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":22861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213012,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-06","kind":"exercise","acquired":true,"shares":18223,"price":0.8411,"value":15327.3653,"ownership":{"direct":true},"balance_after":41084,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213011,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":27000,"price":6,"value":162000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":22861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213010,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-05","kind":"exercise","acquired":true,"shares":27000,"price":0.8411,"value":22709.7,"ownership":{"direct":true},"balance_after":49861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213009,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":27000,"price":6,"value":162000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":22861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213008,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-07-01","kind":"exercise","acquired":true,"shares":27000,"price":0.8411,"value":22709.7,"ownership":{"direct":true},"balance_after":49861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2213007,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-07-06T17:19:43.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":6183,"price":2.1165,"value":13086.3195,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":22861,"source":{"system":"sec-edgar","filing":"0000891293-22-000034","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000034/primary_doc.xml","form_type":"4"}},{"id":2246059,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-03T19:15:06.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":18223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1227777,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":18223},"source":{"system":"sec-edgar","filing":"0000891293-22-000028","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000028/primary_doc.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2246058,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-03T19:15:06.000Z","date":"2022-06-02","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1246000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000028","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000028/primary_doc.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2246057,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-03T19:15:06.000Z","date":"2022-06-01","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1273000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000028","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000028/primary_doc.xml","form_type":"4/A","original_submission_date":"2022-06-03"}},{"id":2246056,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":18223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1227777,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":18223},"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246055,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-02","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1246000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246054,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-01","kind":"exercise","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022."}],"balance_after":1273000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246053,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":18223,"price":6.01,"value":109520.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246052,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":18223,"price":0.8411,"value":15327.3653,"ownership":{"direct":true},"balance_after":34901,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246051,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-02","kind":"sale","acquired":false,"shares":27000,"price":6,"value":162000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246050,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-02","kind":"exercise","acquired":true,"shares":27000,"price":0.8411,"value":22709.7,"ownership":{"direct":true},"balance_after":43678,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246049,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-01","kind":"sale","acquired":false,"shares":27000,"price":6,"value":162000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2246048,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2022-06-03T18:16:41.000Z","date":"2022-06-01","kind":"exercise","acquired":true,"shares":27000,"price":0.8411,"value":22709.7,"ownership":{"direct":true},"balance_after":43678,"source":{"system":"sec-edgar","filing":"0000891293-22-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129322000027/primary_doc.xml","form_type":"4"}},{"id":2338452,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T19:39:15.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":1115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates."}],"balance_after":1115000,"derivative":{"exercise_price":4.49,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":1115000},"source":{"system":"sec-edgar","filing":"0000899243-22-010768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010768/doc4.xml","form_type":"4"}},{"id":2338451,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-11T19:39:15.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":3178,"price":2.108,"value":6699.224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0000899243-22-010768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010768/doc4.xml","form_type":"4"}},{"id":2489689,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2021-12-02T17:16:07.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":2178,"price":1.525,"value":3321.45,"ownership":{"direct":true},"balance_after":13500,"source":{"system":"sec-edgar","filing":"0000891293-21-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129321000045/primary_doc.xml","form_type":"4"}},{"id":2489688,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2021-12-02T17:16:07.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":1322,"price":1.5249,"value":2015.9178,"ownership":{"direct":true},"balance_after":11322,"source":{"system":"sec-edgar","filing":"0000891293-21-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129321000045/primary_doc.xml","form_type":"4"}},{"id":2489687,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"common stock","published_at":"2021-12-02T17:16:07.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":5000,"price":2.125,"value":10625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000891293-21-000045","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129321000045/primary_doc.xml","form_type":"4"}},{"id":2793071,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-12T18:38:07.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date."}],"balance_after":800000,"derivative":{"exercise_price":3.3,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000899243-21-011360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924321011360/doc4.xml","form_type":"4"}},{"id":2793070,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-12T18:38:07.000Z","date":"2020-07-01","kind":"grant","acquired":true,"shares":5000,"price":0.98,"value":4900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-21-011360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924321011360/doc4.xml","form_type":"4"}},{"id":3212034,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-qualified Stock Option","published_at":"2020-03-13T19:30:02.000Z","date":"2020-03-11","kind":"grant","acquired":true,"shares":2320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date."}],"balance_after":2320000,"derivative":{"exercise_price":1,"expiration_date":"2030-03-11","underlying":"Common stock","underlying_shares":2320000},"source":{"system":"sec-edgar","filing":"0000891293-20-000014","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129320000014/primary_doc.xml","form_type":"4"}},{"id":3519476,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-05-20T16:41:26.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying the option will vest on February 19, 2020, and one-third of the shares underlying the option will vest annually thereafter, such that all of the shares subject to the option will be vested and exercisable on February 19, 2022, subject to Dr. Craig continuing to be an employee or a service provider through each such date."}],"balance_after":1300000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0000891293-19-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129319000042/primary_doc.xml","form_type":"4"}},{"id":3811065,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-09-20T16:46:05.000Z","date":"2018-09-18","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in six equal semi-annual installments over a three-year period commencing on September 18, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on September 18, 2021."}],"balance_after":600000,"derivative":{"exercise_price":1.88,"expiration_date":"2028-09-18","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000891293-18-000086","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129318000086/primary_doc.xml","form_type":"4"}},{"id":3929282,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-05-17T17:07:52.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":475000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in six equal semi-annual installments over a three-year period commencing on March 9, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on March 9, 2021."}],"balance_after":475000,"derivative":{"exercise_price":4.14,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0000891293-18-000059","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129318000059/primary_doc.xml","form_type":"4"}},{"id":4196138,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-10-03T17:16:14.000Z","date":"2017-09-29","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in six equal installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates."}],"balance_after":450000,"derivative":{"exercise_price":3.19,"expiration_date":"2027-09-29","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000891293-17-000108","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129317000108/primary_doc.xml","form_type":"4"}},{"id":4376907,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":23649,"kind":"person","name":"Craig Adam R","position":1,"cik":"0001339498","reported_name":"Craig Adam R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-21T19:09:06.000Z","date":"2017-03-20","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest in six equal semi-annual installments over a three-year period beginning March 20, 2017, subject to Dr. Craig's continued employment by CTIC through the applicable vesting dates. The options will fully vest, to the extent then outstanding and unvested, if either (i) Dr. Craig's employment is terminated by CTIC without \"Cause\" or by him for \"Good Reason\" following a change in control of CTIC or (ii) Dr. Craig's employment is terminated due to his death or \"Disability\" (as such terms are defined in Dr. Craig's Employment Agreement).  Of the total award, stock options covering 80,000 shares were granted under CTIC's 2015 Equity Incentive Plan and the balance were granted on a stand-alone basis (not under CTIC's 2015 Equity Incentive Plan) in accordance with NASDAQ Listing Rule 5635(c)(4)."}],"balance_after":1200000,"derivative":{"exercise_price":4.24,"expiration_date":"2027-03-19","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000899243-17-008320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924317008320/doc4.xml","form_type":"4"}}]}